The British government is looking to bring biosimilars under the country’s statutory price controls starting in 2019.
According to a Center for Biosimilars report, the government launched a consultation that details proposed changes to country’s price controls. The price controls were reportedly introduced in March.
Current price controls apply to brand-name products whose sponsors decline the Pharmaceutical Price Regulation Scheme (PPRS), a voluntary scheme negotiated between the Association of the British Pharmaceutical Industry and U.K. Department of Health.
The PPRS also restricts how much a drugmaker can make off drugs sold to the National Health Service.